Cancer Drug Design and Discovery

Informationen zum Autor Stephen Neidle is an Emeritus Professor of Chemical Biology at University College London, where he has also been the Director of Research in the School of Pharmacy. He has published over 500 primary papers and reviews and is a principal inventor on 14 patent filings. He has also written and edited several books on nucleic acids and anti-cancer drugs. Klappentext Using Information to Develop a Culture of Customer Centricity sets the stage for understanding the holistic marriage of information, socialization, and process change necessary for transitioning an organization to customer centricity. The book begins with an overview list of 8-10 precepts associated with a business-focused view of the knowledge necessary for developing customer-oriented business processes that lead to excellent customer experiences resulting in increased revenues. Each chapter delves into each precept in more detail.Focuses on the underlying principles for the design and subsequent development of new anticancer small molecule agents. This book includes several sections on the basic and applied science of cancer drug discovery and features those drugs that are approved for human use and are in the marketplace, as well as those that are still under development. Inhaltsverzeichnis Introduction - Stephen Neidle Foreword - Hilary Calvert Part I. Basic Principles and methodology Modern cancer drug discovery: integrating targets, technologies and treatments - Paul Workman and Ian Collins Pharmacogenomics and personalised medicines in cancer treatment - Wei-Peng Yong, Ross Soo and Federico Innocenti Structural biology and anticancer drug design - Puja Pathuri, David Norton, Henriette Willems, Dominic Tisi and Harren Jhoti Part II. Drugs in the laboratory and clinic Temozolomide: from cytotoxic to molecularly-targeted agent - Malcolm Stevens Temozolomide: patents and the perils of invention - Malcolm Stevens A new generation of cell-targeted drugs for cancer treatment - Paola B. Arimondo, Nicolas Guilbaud and Christian Bailly Inhibition of DNA repair as a therapeutic target - Stephany Veuger and Nicola J Curtin Inhibitors of tumour angiogenesis - Adrian L. Harris and Daniele G Generali The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer - Qingzhong Hu and Rolf W. Hartmann Apoptosis in Cancer: Mechanisms, Deregulation and Therapeutic Targeting - Zahid H Siddik Targeting the MDM2-p53 protein-protein interaction: design, discovery and development of novel anticancer agents - Ian R Hardcastle Targeting altered metabolism - emerging cancer therapeutic strategy - Minsuh Seo, Robert Blake Crochet and Yong-Hwan Lee Inhibitors of the Phosphatidylinositol 3-kinase (PI3K) Pathway - William A Denny and Gordon W. Rewcastle Antibody-drug conjugates delivering DNA cytotoxics - John A Hartley Inhibition of telomerase: promise, progress and potential pitfalls - Christopher G. Tomlinson, Scott B. Cohen and Tracy M. Bryan Targeting B-RAF: the discovery and development of B-RAF inhibitors - Phillip A Harris Part III. The reality of cancer drugs in the clinic Failure Modes in Anticancer Drug Discovery and Development - Richard A. Walgren and Christopher. A. Slapak Anticancer drug registration and regulation: current challenges and possible solutions - David Taylor, Erling Donnelly and Silvia Chioato ...

List of contents

Introduction - Stephen Neidle
Foreword - Hilary Calvert
Part I. Basic Principles and methodology
Modern cancer drug discovery: integrating targets, technologies and treatments - Paul Workman and
Ian Collins
Pharmacogenomics and personalised medicines in cancer treatment - Wei-Peng Yong, Ross Soo and
Federico Innocenti
Structural biology and anticancer drug design - Puja Pathuri, David Norton, Henriette Willems,
Dominic Tisi and Harren Jhoti
Part II. Drugs in the laboratory and clinic
Temozolomide: from cytotoxic to molecularly-targeted agent - Malcolm Stevens
Temozolomide: patents and the perils of invention - Malcolm Stevens
A new generation of cell-targeted drugs for cancer treatment - Paola B. Arimondo, Nicolas Guilbaud
and Christian Bailly
Inhibition of DNA repair as a therapeutic target - Stephany Veuger and Nicola J Curtin
Inhibitors of tumour angiogenesis - Adrian L. Harris and Daniele G Generali
The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer - Qingzhong Hu and Rolf
W. Hartmann
Apoptosis in Cancer: Mechanisms, Deregulation and Therapeutic Targeting - Zahid H Siddik
Targeting the MDM2-p53 protein-protein interaction: design, discovery and development of novel
anticancer agents - Ian R Hardcastle
Targeting altered metabolism - emerging cancer therapeutic strategy - Minsuh Seo, Robert Blake
Crochet and Yong-Hwan Lee
Inhibitors of the Phosphatidylinositol 3-kinase (PI3K) Pathway - William A Denny and Gordon W.
Rewcastle
Antibody-drug conjugates delivering DNA cytotoxics - John A Hartley
Inhibition of telomerase: promise, progress and potential pitfalls - Christopher G. Tomlinson, Scott B.
Cohen and Tracy M. Bryan
Targeting B-RAF: the discovery and development of B-RAF inhibitors - Phillip A Harris
Part III. The reality of cancer drugs in the clinic
Failure Modes in Anticancer Drug Discovery and Development - Richard A. Walgren and
Christopher. A. Slapak
Anticancer drug registration and regulation: current challenges and possible solutions - David
Taylor, Erling Donnelly and Silvia Chioato

Report

".offers unique information on the discovery and design of new anticancer agents, covering recent notable successes resulting from the human genome and cancer genomics projects.an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry." --Anticancer Research 34, 2014
"The second edition of this book walks readers through the myriad cancer drugs and their molecular targets, with a special emphasis on past, present, and future drug design efforts... the book examines both drugs currently in the clinic and those merely on the drawing board.This comprehensive update of the 2008 edition will serve student or experienced cancer researchers well as a reference on anticancer drug development." Rating: 4 Stars --Doody.com, March 21, 2014
"Specialists in cancer and pharmaceuticals, most in academic settings, look at basic principles of cancer drugs, methodology, drugs in the clinic, new agents, and the reality of cancer drugs in the clinic.They do include many case studies, and some chapters provide questions for classroom use." --ProtoView.com, February 2014

Product details

• Authors: Stephen Neidle, Stephen (EDT) Neidle
• Assisted by: Stephen Neidle (Editor), Stephen (The School of Pharmacy Neidle (Editor), Neidle Stephen (Editor)
• Publisher: Academic Press London
• Languages: English
• Product format: Hardback
• Released: 16.11.2013
• EAN: 9780123965219
• ISBN: 978-0-12-396521-9
• No. of pages: 640
• Series: Academic Press
• Subjects: Natural sciences, medicine, IT, technology > Medicine > Pharmacy; Pharmakologie, MEDICAL / Pharmacology, Oncology, Pharmacology, MEDICAL / Oncology / General